Regarding new therapies, apparently PCSK9 inhibitors have a similar effect on lowering the LDLc level, apoB and non-HDLc in patients with CKD stage 3–5 (CrCl 30–59 mL/min/1.73 m2) and in patients with a normal renal function. Here, PCSK9 is linked to chronic kidney disease.